<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831126</url>
  </required_header>
  <id_info>
    <org_study_id>PerFet_maternal_stress_fMEG</org_study_id>
    <nct_id>NCT03831126</nct_id>
  </id_info>
  <brief_title>Stress and Fetal Brain Development</brief_title>
  <official_title>The Impact of Stress on Fetal Brain Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current proposal aims to investigate the impact of acute stress on the fetal autonomic&#xD;
      nervous system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the last decades there is growing evidence that increased maternal stress levels lead to&#xD;
      an adverse effect on the physiological, metabolic and neuronal development of the fetus&#xD;
      during gestation with possible long-lasting effects. Several studies showed that maternal&#xD;
      stress also affects fetal endocrine processes during pregnancy and increases the risk for&#xD;
      childhood and adult obesity. Thus, the aim of the study is to investigate the effect of acute&#xD;
      stress related to the action of the artificial glucocorticoid betamethasone on fetal heart&#xD;
      and brain activity. The fetal activity will be measured with biomagnetic sensors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fetal and maternal heart rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement by fMEG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fetal and neonatal brain activity in response to auditory and visual stimuli</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement by fMEG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood sugar levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement by fMEG</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>betamethasone treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethason Sodium Phosphate</intervention_name>
    <description>First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh</description>
    <arm_group_label>betamethasone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  German speakers (fluently)&#xD;
&#xD;
          -  Gestational age between 28 and 34 weeks&#xD;
&#xD;
          -  Treatment with Betamethasone for improvement of fetal lung function -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking (regularly)&#xD;
&#xD;
          -  Alcohol and drug consumption during pregnancy&#xD;
&#xD;
          -  Congenital fetal disorders&#xD;
&#xD;
          -  Women with bed rest&#xD;
&#xD;
          -  acute depression or other psychiatric disorder (self report)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Pauluschke-Fr√∂hlich, MD</last_name>
    <phone>07071 2983111</phone>
    <email>jan.pauluschke-froehlich@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Tuebingen, Department of Women's Health</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Linneweh, Dr</last_name>
      <phone>+4970712982211</phone>
      <email>miriam.linneweh@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

